The strong Phase 1a data for ATI-052 significantly de-risks the asset and supports a best-in-class profile, likely driving near-term upside. Key catalysts to watch: Phase 1b top-line data in asthma/AD (H2 2026) and initiation of Phase 2b programs. The LP indication for ATI-2138 opens a large unaddressed market; monitor enrollment updates.
Price Chart
Executive Summary
Aclaris reported positive full Phase 1a results for ATI-052, an anti-TSLP/IL-4Rα bispecific antibody, showing a 45-day half-life and complete sustained target inhibition, supporting up to every-three-month dosing. The company also selected lichen planus as the lead indication for ATI-2138, an ITK/JAK3 inhibitor, with a Phase 2b basket study expected to start in H2 2026. These updates de-risk the pipeline and expand the addressable market opportunity, though both assets remain in early-stage development with no revenue or near-term catalysts.
Key Facts
- ATI-052 Phase 1a results show estimated half-life of ~45 days, supporting up to every-three-month dosing.
- Complete and sustained inhibition of TSLP- and IL-4-induced CCL17/TARC through at least week 20 (four months post last dose) in the 480 mg MAD cohort.
- No impact of anti-drug antibodies on PK or PD observed; favorable safety profile with no conjunctivitis.
- Phase 1b trials in asthma and atopic dermatitis are enrolling; top-line results expected H2 2026.
- Phase 2b program for ATI-052 in asthma to initiate in Q4 2026.
- Lichen planus selected as lead indication for ATI-2138; Phase 2b basket study (erosive mucosal, cutaneous, LPP) to start H2 2026.
- Company estimates U.S. market opportunity for an oral LP therapeutic exceeds $1.0B, up to $4.0B.
- No FDA-approved therapies exist for lichen planus; ~40% of patients seek treatment.
- Management to host conference call at 8:30 AM ET today.
Financial Impact
No financial data reported; potential market opportunity for ATI-2138 in LP estimated at $1B-$4B in the U.S.
Risk Factors
- Phase 1b and Phase 2b trials may fail to replicate Phase 1a results in patient populations.
- Competition from approved biologics (e.g., dupilumab, tezepelumab) in asthma/AD could limit ATI-052's commercial potential.
- ATI-2138 faces regulatory and clinical development risks in a disease with no approved therapies.
- No revenue or near-term profitability; reliance on capital markets for funding.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3282383 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | Institutional Cluster | $5.84 $6.44 | ▲ +10.27% | ▲ +10.72% | $3.79 (−35.10%) |
Aug 6, 2026 11w ago | 8-K | $6.09 $5.86 | ▼ −3.78% | ▼ −4.99% | $3.79 (−37.77%) |
Apr 28, 2026 25w ago | 8-K | $4.22 $4.75 | ▲ +12.56% | ▲ +10.87% | $3.79 (−10.19%) |
Apr 28, 2026 25w ago | Press Release | $4.22 $4.75 | ▲ +12.56% | ▲ +10.87% | $3.79 (−10.19%) |
Apr 23, 2026 26w ago | DEFA14A | $4.55 $4.47 | ▼ −1.76% | ▼ −3.24% | $3.79 (−16.70%) |
Mar 27, 2026 30w ago | Press Release | $3.52 $3.80 | ▲ +7.95% | ▲ +4.09% | $3.79 (+7.67%) |
Mar 20, 2026 31w ago | Press Release | $3.69 $3.52 | ▼ −4.61% | ▼ −2.46% | $3.79 (+2.71%) |
Mar 18, 2026 31w ago | Press Release | $3.66 $3.59 | ▼ −1.91% | ▼ −1.20% | $3.79 (+3.55%) |
Mar 11, 2026 32w ago | 8-K | $3.51 $3.74 | ▲ +6.55% | ▲ +7.53% | $3.79 (+7.98%) |
Feb 28, 2026 34w ago | Institutional Cluster | $3.05 $3.39 | ▲ +11.15% | ▲ +12.36% | $3.79 (+24.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers